Aptose Biosciences (APS) Price & Analysis

Compare

145 Followers

APS Stock Chart & Stats

Day’s Range― - ―

52-Week RangeC$1.98 - C$38.40

Previous CloseN/A

Volume48.76K

Average Volume (3M)4.24K

Market Cap

$6.07M

Enterprise ValueC$760.70M

Total Cash (Recent Filing)$4.70M

Total Debt (Recent Filing)$8.98M

Price to Earnings (P/E)―

Beta-1.40

Next Earnings

Aug 07, 2025

EPS Estimate

-3.82

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.64

Shares Outstanding2,552,429

10 Day Avg. Volume2,193

30 Day Avg. Volume4,238

Financial Highlights & Ratios

PEG Ratio0.20

Price to Book (P/B)21.10

Price to Sales (P/S)0.00

P/FCF Ratio-24.62

Enterprise Value/Market Cap125.22

Enterprise Value/Revenue398.16

Enterprise Value/Gross Profit-6.45K

Enterprise Value/Ebitda-6.22

Forecast

1Y Price Target

$8.16

Price Target Upside228.91% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Aptose Biosciences News

PremiumCompany Announcements

Aptose Biosciences Secures Cash Advance Amid Financial Uncertainty

6h ago

PremiumCompany Announcements

Aptose Biosciences Reports Promising Results from TUSCANY Trial in AML

5d ago

PremiumCompany Announcements

Aptose Biosciences Approves Key Resolutions at Shareholder Meeting

20d ago

PremiumCompany Announcements

Aptose Biosciences Begins 120 mg Dosing in TUSCANY Trial

28d ago

PremiumCompany Announcements

Aptose’s TUSCANY Trial Data to be Presented at EHA 2025

1M ago

PremiumCompany Announcements

Aptose Biosciences Reports Q1 2025 Financial Results

1M ago

PremiumCompany Announcements

Aptose Biosciences Reports Promising AML Trial Results and Expands Market Presence

1M ago

PremiumCompany Announcements

Aptose Biosciences Reports Promising Results from TUSCANY Trial for AML Treatment

1M ago

See All TSE:APS News

See All News >

Bulls Say, Bears Say

Bulls Say

Clinical ProgressAptose has made progress in progressing tuspetinib in the clinic, including initiating and reporting early safety and efficacy data from TUSCANY, a Phase 1/2 triplet combo study in newly diagnosed acute myeloid leukemia.

Financial StabilityThe company ended the year with $6.7 million in cash, which management believes should provide runway for ongoing operations through April 2025.

PartnershipsAptose is working with its partner Hanmi Pharmaceutical to negotiate a new tuspetinib co-development collaboration agreement designed to provide necessary additional funding and accelerate clinical development.

Bears Say

Funding UncertaintyAptose is working with its partner Hanmi Pharmaceutical to negotiate a new tuspetinib co-development collaboration agreement to provide necessary additional funding and accelerate clinical development of tuspetinib.

Market CompetitionThe TUSCANY trial could position TUS as a promising combination therapy for larger AML populations, avoiding the toxicities observed with other agents.

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

24.03% Insiders

<0.01%

Mutual Funds

5.44% Other Institutional Investors

70.53% Public Companies and Individual Investors

Detailed Ownership Overview >

APS FAQ

What was Aptose Biosciences’s price range in the past 12 months?

Aptose Biosciences lowest stock price was C$1.98 and its highest was C$38.40 in the past 12 months.

What is Aptose Biosciences’s market cap?

Aptose Biosciences’s market cap is $6.07M.

When is Aptose Biosciences’s upcoming earnings report date?

Aptose Biosciences’s upcoming earnings report date is Aug 07, 2025 which is in 51 days.

How were Aptose Biosciences’s earnings last quarter?

Aptose Biosciences released its earnings results on May 08, 2025. The company reported -C$3.637 earnings per share for the quarter, beating the consensus estimate of -C$3.721 by C$0.084.

Is Aptose Biosciences overvalued?

According to Wall Street analysts Aptose Biosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Aptose Biosciences pay dividends?

Aptose Biosciences does not currently pay dividends.

What is Aptose Biosciences’s EPS estimate?

Aptose Biosciences’s EPS estimate is -3.82.

How many shares outstanding does Aptose Biosciences have?

Aptose Biosciences has 2,552,429 shares outstanding.

What happened to Aptose Biosciences’s price movement after its last earnings report?

Aptose Biosciences reported an EPS of -C$3.637 in its last earnings report, beating expectations of -C$3.721. Following the earnings report the stock price went up 3.256%.

Which hedge fund is a major shareholder of Aptose Biosciences?

Currently, no hedge funds are holding shares in TSE:APS

Company Description

Aptose Biosciences

Aptose Biosciences Inc. (APS) is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of highly differentiated therapeutics addressing unmet medical needs in oncology. The company specializes in developing targeted therapies for the treatment of hematologic malignancies and other life-threatening diseases. Aptose leverages a deep understanding of cancer biology to develop innovative small molecule cancer drugs.

APS Stock 12 Month Forecast

Average Price Target

C$8.16

▲(228.91%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"C$3","31":"C$31","59":"C$59","87":"C$87","115":"C$115"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8.15690622,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">C$8.16</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.15690622,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">C$8.16</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.15690622,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">C$8.16</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,31,59,87,115],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2024","6":"Jun<br/>2024","9":"Dec<br/>2024","12":"Mar<br/>2025","25":"Mar<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.36,4.652069709230769,4.944139418461539,5.236209127692308,5.528278836923077,5.820348546153847,6.112418255384616,6.4044879646153845,6.696557673846154,6.988627383076923,7.280697092307692,7.572766801538462,7.864836510769231,{"y":8.15690622,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.36,4.652069709230769,4.944139418461539,5.236209127692308,5.528278836923077,5.820348546153847,6.112418255384616,6.4044879646153845,6.696557673846154,6.988627383076923,7.280697092307692,7.572766801538462,7.864836510769231,{"y":8.15690622,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.36,4.652069709230769,4.944139418461539,5.236209127692308,5.528278836923077,5.820348546153847,6.112418255384616,6.4044879646153845,6.696557673846154,6.988627383076923,7.280697092307692,7.572766801538462,7.864836510769231,{"y":8.15690622,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":114,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":109.05,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.2,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.8,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.299,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.8,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.2,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.9,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.9,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.5,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.75,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.649,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.36,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >